In the US,<unk>  (while approved) was contraindicated in people with liver impairment, including significantly elevated liver enzymes (ALT, AST) and autoimmune hepatitis. The European Medicines Agency (EMA) originally approved the drug without any contraindications apart from known hypersensitivity, but required Biogen to implement a hepatic risk management guide for physicians. In July 2017, the EMA has issued a provisional contraindication for patients with pre-existing liver disease or liver impairment. The marketing authorisation was withdrawn in the EU on 27 March 2018. An EMA review concluded that the medicine poses a risk of serious and potentially fatal immune reactions affecting the brain, liver and other organs.
Daclizumab
Tocilizumab
Brolucizumab
Satralizumab
Ravulizumab
Reslizumab
Natalizumab
Benralizumab